Online inquiry

IVTScrip™ mRNA-Anti-SNCA, BIIB-054(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ4291MR)

This product GTTS-WQ4291MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets SNCA gene. The antibody can be applied in Parkinson's disease (PD) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000345.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 6622
UniProt ID P37840
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-SNCA, BIIB-054(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ4291MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6282MR IVTScrip™ mRNA-Anti-CD274, CS-1001(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CS-1001
GTTS-WQ15963MR IVTScrip™ mRNA-Anti-NGF, ZTS-00508841(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ZTS-00508841
GTTS-WQ13695MR IVTScrip™ mRNA-Anti-ERBB2, RC48(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA RC48
GTTS-WQ4161MR IVTScrip™ mRNA-Anti-PDCD1, BI-754091(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BI-754091
GTTS-WQ9058MR IVTScrip™ mRNA-Anti-FLT1, IMC-18F1(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA IMC-18F1
GTTS-WQ10689MR IVTScrip™ mRNA-Anti-TNFSF13B, LymphoStat-B(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA LymphoStat-B
GTTS-WQ5512MR IVTScrip™ mRNA-Anti-IL17A&IL17F, CDP4940(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA CDP4940
GTTS-WQ14131MR IVTScrip™ mRNA-Anti-PCSK9, aPCSK927(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA aPCSK927
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW